Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Last trade$95.85
Day change-$0.655 (-0.68%)
Day range$95.02 – $98.95
Volume941,271
Market cap$11.00B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11B
Price / earnings
22.66×
Price / book
-199.17×
Price / sales
6.1×
EV / sales
7.34×
EV / EBITDA
11.64×
Profitability
Earnings per share
$4.26
Return on assets
13.98%
Return on equity
-878.76%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-58.84×
Current ratio
3.88×
Quick ratio
3.6×
Cash ratio
2.16×
Cash flow
Price / cash flow
12.25×
Price / free cash flow
12.42×
Free cash flow
$885.88M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HALO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$492.97M
$481M
$376.71M
$451.77M
$354.26M
$325.72M
$264.86M
$298.01M
Cost of revenue
$82.48M
$79.17M
$79.24M
$78.77M
$55.24M
$46.36M
$48.4M
$42.06M
Gross profit
$410.5M
$401.83M
$297.47M
$373M
$299.02M
$279.36M
$216.46M
$255.95M
Selling, general and administrative
$58.24M
$57M
$57.88M
$77.03M
$46.09M
$41.61M
$42.36M
$42.25M
Research and development
$27.78M
$27.66M
$25.56M
$31.9M
$17.25M
$17.54M
$14.8M
$20.44M
Total operating expenses
$115.53M
$114.17M
$112.95M
$417.19M
$81.1M
$76.92M
$74.92M
$80.45M
Operating income
$294.97M
$287.65M
$184.52M
-$44.19M
$217.92M
$202.44M
$141.54M
$175.5M
Interest expense
-$6.05M
-$5.59M
-$5.51M
-$4.91M
-$4.3M
-$4.39M
-$4.53M
-$4.54M
Income before taxes
$290.63M
$284.9M
$180.33M
-$100.85M
$218.96M
$204.94M
$143.83M
$178.21M
Income taxes
$43.58M
$54.99M
$30.28M
$40.74M
$43.73M
$39.78M
$25.73M
$41.2M
Net income
$247.05M
$229.91M
$150.05M
-$141.59M
$175.23M
$165.16M
$118.1M
$137.01M
Net income attributable to common shareholders
$247.05M
$229.91M
$150.05M
-$141.59M
$175.23M
$165.16M
$118.1M
$137.01M
EBITDA
$329.17M
$321.62M
$218.25M
$267.38M
$238.34M
$222.94M
$161.98M
$195.92M
Basic earnings per share
$2.17
$1.96
$1.27
-$1.20
$1.49
$1.36
$0.96
$1.08
Diluted earnings per share
$2.01
$1.90
$1.22
-$1.16
$1.43
$1.33
$0.93
$1.06
Recent news
Company coverage with links to the original publishers.
Halozyme Therapeutics (HALO) has surged 43.1% over six months, outperforming the industry and S&P 500, driven by strong royalty revenues from its ENHANZE drug delivery technology partnerships. The company raised 2026 guidance with total revenues expected to reach $1.86-$1.925 billion and royalty revenues of $1.24-$1.26 billion. While recent acquisitions and proprietary product growth support long-term prospects, heavy reliance on partner companies for royalty income remains a key risk. Zacks rates the stock as a Hold.
Halozyme Therapeutics raised its 2026 revenue guidance to $1.86-$1.925 billion (33-38% YoY growth) and royalty revenue guidance to $1.24-$1.26 billion (42-45% YoY growth), driven by increased royalties from partnered drugs including J&J's Darzalex, argenx's Vyvgart Hytrulo, and Roche's Phesgo. The company's stock has rallied 53% year-to-date, though it trades at a premium valuation compared to the industry.
Halozyme Therapeutics (HALO) is highlighted as a strong growth stock pick with a Zacks Rank #1 and Growth Score of A. The company demonstrates exceptional earnings growth of 112.9% expected this year (versus 17.5% industry average), efficient asset utilization with an S/TA ratio of 0.64 (double the industry average of 0.34), and positive earnings estimate revisions. Sales are projected to grow 35.8% this year compared to 0% industry average.
TG Therapeutics reported Q3 2026 EPS of 35 cents and revenues of $259.9 million, both beating consensus estimates. Briumvi U.S. sales surged 52% to $232.6 million driven by physician adoption and patient growth. The company raised its 2026 global revenue guidance to $1 billion and expects Q4 U.S. Briumvi sales above $260 million. The stock rose 5.9% following the results.
Following NVIDIA's governance controversy and 4.27% stock plunge, investors are advised to diversify away from concentrated AI exposure. The article recommends redirecting capital toward defensive sectors like healthcare and consumer staples, while maintaining selective semiconductor exposure through alternative players like TSMC and Semtech.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.